108
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update

Pages 3111-3119 | Published online: 12 Nov 2008
 

Abstract

Background: Bisphosphonates are the standard of care for treating and preventing the complications of bone metastases. Ibandronic acid is available in effective and well-tolerated oral (50 mg daily) and intravenous (6 mg via ≥ 15 min infusion every 3 – 4 weeks) formulations. Objectives: This paper reviews the latest preclinical and clinical data supporting the use of ibandronic acid for the prevention and treatment of the skeletal complications of neoplastic bone disease, focusing on metastatic breast cancer. The aim was to update a review of ibandronic acid published in 2004 by the current author. Conclusions: Ibandronate remains the only bisphosphonate with approved oral and intravenous formulations; ibandronate should be considered when designing a bisphosphonate-containing regimen for patients with bone metastases from breast cancer.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 884.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.